Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation.

Cheer JF, Wassum KM, Sombers LA, Heien ML, Ariansen JL, Aragona BJ, Phillips PE, Wightman RM.

J Neurosci. 2007 Jan 24;27(4):791-5.

2.

Endocannabinoid control of food intake and energy balance.

Di Marzo V, Matias I.

Nat Neurosci. 2005 May;8(5):585-9. Review.

PMID:
15856067
3.

The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.

Xie S, Furjanic MA, Ferrara JJ, McAndrew NR, Ardino EL, Ngondara A, Bernstein Y, Thomas KJ, Kim E, Walker JM, Nagar S, Ward SJ, Raffa RB.

J Clin Pharm Ther. 2007 Jun;32(3):209-31. Review.

PMID:
17489873
4.

CB1 receptor antagonists for the treatment of nicotine addiction.

Cohen C, Kodas E, Griebel G.

Pharmacol Biochem Behav. 2005 Jun;81(2):387-95. Review.

PMID:
15935455
5.

Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).

van Diepen H, Schlicker E, Michel MC.

Naunyn Schmiedebergs Arch Pharmacol. 2008 Oct;378(4):345-69. doi: 10.1007/s00210-008-0327-2. Epub 2008 Jul 25. Review.

PMID:
18654765
6.

Drug addiction.

Justinova Z, Panlilio LV, Goldberg SR.

Curr Top Behav Neurosci. 2009;1:309-46. doi: 10.1007/978-3-540-88955-7_13. Review.

7.

Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk.

Mach F, Montecucco F, Steffens S.

Pharmacol Rep. 2009 Jan-Feb;61(1):13-21. Review.

8.

The endocannabinoid system as a novel approach for managing obesity.

Lillo JL.

J Am Osteopath Assoc. 2007 Apr;107(4 Suppl 2):S12-20. Review.

PMID:
17784530
9.

Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.

Leite CE, Mocelin CA, Petersen GO, Leal MB, Thiesen FV.

Pharmacol Rep. 2009 Mar-Apr;61(2):217-24. Review.

10.

The endocannabinoid system: a new target for the regulation of energy balance and metabolism.

Després JP.

Crit Pathw Cardiol. 2007 Jun;6(2):46-50. Review.

PMID:
17667864
11.

Functional correlates of nicotine administration: similarity with drugs of abuse.

Pontieri FE, Passarelli F, Calò L, Caronti B.

J Mol Med (Berl). 1998 Mar;76(3-4):193-201. Review.

PMID:
9535552
12.
13.

An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives.

Fattore L, Spano MS, Deiana S, Melis V, Cossu G, Fadda P, Fratta W.

Brain Res Rev. 2007 Jan;53(1):1-16. Epub 2006 Jul 12. Review.

PMID:
16839608
14.

In vivo neurochemical effects induced by changes in endocannabinoid neurotransmission.

Degroot A, Nomikos GG.

Curr Opin Pharmacol. 2007 Feb;7(1):62-8. Epub 2006 Dec 15. Review.

PMID:
17174603
15.

Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders.

Beardsley PM, Thomas BF, McMahon LR.

Int Rev Psychiatry. 2009 Apr;21(2):134-42. doi: 10.1080/09540260902782786. Review.

PMID:
19367507
16.

Tales from the dark side: do neuromodulators of drug withdrawal require changes in endocannabinoid tone?

Oleson EB, Cachope R, Fitoussi A, Cheer JF.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jul 3;52:17-23. doi: 10.1016/j.pnpbp.2013.07.019. Epub 2013 Aug 1. Review.

17.

Illicit dopamine transients: reconciling actions of abused drugs.

Covey DP, Roitman MF, Garris PA.

Trends Neurosci. 2014 Apr;37(4):200-10. doi: 10.1016/j.tins.2014.02.002. Epub 2014 Mar 20. Review.

18.

Rapid Dopamine Release in Freely Moving Rats.

Robinson DL, Wightman RM.

In: Michael AC, Borland LM, editors. Electrochemical Methods for Neuroscience. Boca Raton (FL): CRC Press/Taylor & Francis; 2007. Chapter 2.

Items per page

Supplemental Content

Write to the Help Desk